http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
김부성,김석윤,Kim, Boo-Sung,Kim, Seok-Yoon 대한전자공학회 1999 電子工學會論文誌, C Vol.c36 No.8
빠르고 정확한 결과를 얻기 위해서 타이밍 수준에서의 회로 해석이 이루어지며, 게이트와 연결선에서의 신호 지연 해석은 회로의 설계 검증을 위하여 필수적이다. 본 논문에서는 CMOS 회로 게이트에서의 지연 시간과 연결선의 지연 해석을 위한 초기 천이 시간을 동시에 계산할 수 있는 방법을 제시한다. 회로 연결선의 유효 커패시턴스 개념을 이용하여 게이트의 지연 시간과 게이트에서의 구동 저항을 고려한 연결선 선형 전압원의 천이 시간을 계산한다. 게이트 지연과 연결선 선형 전압원의 천이 시간을 구하는 과정은 예비 특성화된 게이트 타이밍 데이터를 이용하여 반복적인 연산과정을 통하여 동시에 구하게 된다. 기존의 게이트 지연 계산 알고리즘은 연결선 선형 전압원의 천이 시간을 위해 별도의 게이트 특성 데이터를 필요로 하였으나, 본 논문에서 제시하는 방법은 계산 과정 중에 생성된 데이터를 이용함으로써 현재의 예비 특성화 방법을 수정하지 않고서도 효율적인 타이밍 수준의 게이트 및 연결선 지연 시간 예측이 가능하도록 하였다. Timing-level circuit analyses are used to obtain fast and accurate results, and the analysis of gate and interconnect delay is necessary to validate the correctness of circuit design. This paper proposes an efficient algorithm which simultaneously calculates the gate delay and the transition time of linearized voltage source for subsequent interconnect delay calculation. The notion of effective capacitance is used to calculate the gate delay and the transition time of linearized voltage source which considers the on-resistance of driving gate. The procedure for obtaining the gate delay and the transition time of linearized voltage source has been developed through an iterative operation using the precharacterized data of gates. While previous methods require extra information for the transition time calculation of linearized voltage sources, our method uses the derived data during the gate delay calculation process, which does not require any change in the precharacterization process.
만성위염 환자의 유문부 Gastrin 세포의 분포 및 Gastrin 농도
김부성(Boo Sung Kim),최상욱(Sang Wook Choi),정진우(Jin Wu Jeong),박두호(Doo Ho Park),신여림(Yeo Rim Sim),김명석(Myung Suk Kim),박인선(In Sun Park),정진웅(Jin Woong Chung) 대한내과학회 1989 대한내과학회지 Vol.36 No.1
N/A This study was conducted to investigate the influence of chronic gastritis on the distribution of gastrin (G)-cells and gastrin levels in antral mucosa and blood in Korean patients. Fifty-one subjects were divided into three groups according to histological findings of biopsied specimens by endoscopy: normal subjects, patients with chronic superficial gastritis and patients with chronic atrophic gastritis. The G-cells in the antral mucosa were stained by the immunohistochemical method with gastrin antiserum and the number of G-cell per unit area (1 mm breadth of a 5 ㎛-thick sectioned mucosa) was counted. Gastrin levels in the antral mucosal tissue and plasma were measured by means of radioimmunoassay. The results were as follows: 1) The number of G-cells and the antral tissue gastrin level in normal subjects were 106±36.6 and 10.6±6.2㎍/g, respectively. Plasma gastrin concentrations of the normal subjects in fasting and postprandial states, 20 min and 40 min after ingestion of a meat meal, were 63.1±24.5, 141.8±73.8 and 126.0±62.5 pg/ml, respectively. 2) In patients with chronic superficial gastritis, fasting and postprandial plasma gastrin concentrations increased significantly compared with those of the normal subjects, while the number of the G-cells and antral tissue gastrin were not significantly different from the normal values. 3) In patients with chronic atrophic gastritis, the number of G-cells and antral tissue gastrin levels tended to decrease, but fasting and postprandial plasma gastrin concentrations tended to increase compared with the normal values. 4) No G-cells were observed in the region with intestinal metaplasia. The above results indicate that patients with chronic gastritis showed a marked increase in plasma gastrin concentration while the number of antral G-cells and antral tissue gastrin level decreased.
김부성(Boo Sung Kim),이창돈(Chang Don Lee),정진우(Jin Woo Jeong),최상욱(Sang wook Choi),박영민(Young Min Park),한남익(Nam Ik Han),유석환(Suk Hwan Yu) 대한소화기학회 1989 대한소화기학회지 Vol.21 No.1
N/A Nizatidine is new H2-receptor blocker with a thiazole ring. We evaluate the clinical efficacy and safety of the Nizatidine in 30 cases of endoscopically-proven peptic ulcer diseases. Nizatidine was administered 150 mg twice daily for 4 or 8 weeks and then followed by endoscopy. Overall improvement of peptic ulcer diseases by endoscopic evaluation noted in 26 (86.9%) of 30 patients. 7 out of 8 cases (87.5%) of gastric ulcers and 19 out of 22 cases (86.3%) of duodenal ulcers had been healed in 4 or 8 weeks. Clinical symptoms of peptic ulcer diseases had been improved in 29 out of 30 cases (96.7%) after 4 or 8 weeks medication with Nizatidine. No significant clinical side effects and laboratory changes had been noticed during therapy. In conclusion, nizatidine was effective and safe drug for the treatment of peptic ulcer diseases.
HBsAg 양성 간경화증 환자에서 Anti - HBc IgM 의 임상적 의의
김부성(Boo Sung Kim),이창돈(Chang Don Lee),안성홍(Sung Hong Ahn),박영민(Young Min Park),윤기주(Key Joo Yoon),최성호(Sung Ho choi) 대한소화기학회 1989 대한소화기학회지 Vol.21 No.3
N/A We studied the clinical significance of anti-HBc IgM tested by immunoradiometric assay kit (Sorin) in 45 patients with HBsAg positive liver cirrhosis (LC). Anti-HBc IgM positive LC were 17 and anti-HBc IgM negative LC as a control who was randomly selected were 28. LC with hepatocellularcarcinoma (LC+HCC) were 20 and the positive rate for anti-HBc IgM was 25%, while 48% in LC without hepatocellular carcinoma (LC HCC; n=25). The positive rate for anti-HBc IgM in HBeAg positive LC (n=19) was 52.6%, while 28.6% in HBeAb positive LC (n=21). The positive rate for anti-HBc IgM in HBcAg positive LC+HCC (n=6) was 33%, while 23.1% in HBeAb positive LC+ HCC (n=13). However, a significant correlation between HBeAg positivity and the younger group (group I; 40 y/o) was noted; the frequency for HBeAg and anti-HBc IgM in group I was 60% and 40 %, respectively, while 43% and 39.3% in the older group (group II: between 40 and 59 %), respectively. The ratio between LC+HCC and LC HCC in each age group was (1:3.5) in group I, (1:1.3) in group II, and (2.5:1) in group III (60%). So we could find the aging effect to HBeAg-Ab system and the frequency of HCC; higher positive rate for HBeAg and lower frequency for HCC in the younger group (40%), while higher positive rate for HBeAb and higher frequency for HCC in the older group (60 %). Similar frequencies for both parameters were observed in group II. Therefore, no correlation between anti-HBc IgM and HBeAg-Ab system or HCC were noted practically. There were no correlation between anti-HBc IgM and serum level of ALT, globulin, and AFP (alpha-fetoprotein), or the severity of hepatic failure (represented by Pughs score). In conclusion, this study indicates that anti-HBc IgM is not useful clinically in HBsAg positive liver cirrhosis because of its inability to differentiate LC+HCC from LC-HCC, to distinguish the milder hepatic failure from the severe hepatic failure, to represent the severity or activity of the ongoing inflammation and to predict the development of HCC as one of the high risk factor of HCC in LC. And the aging effect to HBeAg-Ab system and the frequency of HCC in HBsAg positive LC in Korea should be considered.
김부성(Boo Sung Kim),정진우(Jin Wu Jeong),이창돈(Chang Don Lee),이성(Sung Lee),한남익(Nam Ik Han),김병기(Byong Ki Kim),홍설유(Seol Yun Hong),유석환(Suk Hwan Yoo) 대한소화기학회 1989 대한소화기학회지 Vol.21 No.1
Primary adenocarcinoma of the duodenum is an uncommon codition. It represents about 0.3% of all malignant neoplasms of the gastrointestinal tract and 25-45% of malignant neoplasms of the small intestine. The first documented case of the duodenal carcinoma was described by Hamburger 1746. Since then, only 694 cases have been presented in the literature up to the 1974. We have experienced a case of primary duodenal carcinoma, which was diagnosed by biopsies with gastrofibroscopic endoscopy. Therefore, we present here a case of duodenal carcinoma with a review of literture.